CBD-Tacrolimus interaction study completed: key dosing insights for transplant recipients
NCT ID NCT05490511
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how cannabidiol (CBD) interacts with tacrolimus, a drug used to prevent organ rejection in transplant patients. Researchers wanted to understand how to adjust doses for better health outcomes. The study involved 57 healthy adults and those with chronic kidney disease, measuring drug levels and immune responses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CBD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IU Health University Hospital
Indianapolis, Indiana, 46202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can daily CBD reshape your stress response? a study puts it to the test.
- Dialysis's hidden water waste: can a simple flow change cut consumption without harming patients?
- Can cooking classes and exercise outperform medically tailored groceries for heart and kidney health?
- Diabetes drug semaglutide tested in dialysis patients for safety
- Massive UK study tracks cancer after organ transplants
- Can better Doctor-Patient chats boost kidney transplants?